hotspot -WSS

hotspot

author：knowledge 2025-09-30 16:26:22 - browse：9678

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： FDA warns medical device makers about rise in fabricated data

hotspot

WSS

Hospitals are piloting generative AI tools as regulators play catch

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

Obamacare plans could cover weight loss drugs

An outrageous hospital charge: I paid $710 for an hour of babysitting

Ending health disparities requires full federal government, panel says

Medicare Advantage enrollment hits roughly 33.4 million

entertainment

hotspot

explore

Anesthesiologist group: stop taking Ozempic before surgery

Timeline: Special counsel's probe into Trump's handling of classified documents

As demand for Covid shots wanes, Moderna seeks its next success

Medicare Advantage enrollment hits roughly 33.4 million

Moonlake's readout produced a cash windfall. Risks remain

Ford recalls 870K F

Walensky prepares to leave CDC — and Congress — behind

Stoke drug shows lower activity against childhood epilepsy

Continuity nursing helped my family in our darkest PICU moments

Surprise medical billing ban raises prices elsewhere

knowledge

Medicare Advantage enrollment hits roughly 33.4 million

Obamacare plans could cover weight loss drugs

Weight loss drugs aren’t covered by Obamacare. That may change

FDA warns medical device makers about rise in fabricated data

A new drug could help frostbite victims avoid its ravages

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

knowledge

hotspot

hotspot

hotspot